Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Numico baby food division

This article was originally published in The Tan Sheet

Executive Summary

Dutch firm expects annualized net cost savings of roughly $39.5 mil. in 2006 as part of effort to optimize manufacturing platform of its European Baby Food Division. Under plan announced July 7, Numico will reduce number of manufacturing plants from 16 to 9, eliminating 750 jobs and creating 225 new positions at the remaining plants. "Related cost savings will be reinvested in innovation, marketing and sales programs," firm says. Numico also is evaluating its options regarding GNC and recently accepted "informal" bids for the supplement chain; former CEO Bill Watts, along with a U.S. venture capital company, have expressed interest (1"The Tan Sheet" May 12, 2003, In Brief)...

You may also be interested in...



GNC suitor

Bill Watts "has expressed a potential interest in acquiring GNC...in cooperation with a U.S. venture capital company," Royal Numico announces May 9. However, Dutch firm stresses "no decision on a possible future divestment" of the supplement retailer has been made. Watts will step down from Numico's Supervisory Board, firm says during Annual General Meeting of Shareholders. A former GNC CEO, Watts stepped down in March 2000 to join the Supervisory Board (1"The Tan Sheet" Nov. 6, 2000, p. 6)...

QUOTED. 26 February 2020. Mark Leahey.

In an exclusive interview with Medtech Insight, Mark Leahey, president of the Medical Device Manufacturers Association (MDMA), said the previous four Medical Device User Fee negotiations with the US FDA have set a strong foundation for the industry and the next round of negotiations should focus on tweaking past deals that are already in place. See what MDMA's president, Mark Leahey, said about it here.

The Quality Lowdown: On Redeploying Inspectors, API Suppliers Thanks To Coronavirus

US investigators fan out to non-China inspection priorities and Secretary Azar talks supply management; warning letters hit record keeping, investigations and basic GMP compliance.

Topics

UsernamePublicRestriction

Register

PS095689

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel